newsfilter
← Latest News
PR Newswire·

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of...